Terms: = Ovarian cancer AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
14 results:
1. Inhibition of checkpoint kinase prevents human oocyte apoptosis induced by chemotherapy and allows enhanced tumour chemotherapeutic efficacy.
Wu M; Xue L; Chen Y; Tang W; Guo Y; Xiong J; Chen D; Zhu Q; Fu F; Wang S
Hum Reprod; 2023 Sep; 38(9):1769-1783. PubMed ID: 37451671
[TBL] [Abstract] [Full Text] [Related]
2. Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Monk BJ; González-Martin A; Buckley L; Matulonis UA; Rimel BJ; Wu X; Moore KN; Mirza MR
Int J Gynecol Cancer; 2023 Jun; 33(6):971-981. PubMed ID: 36792166
[TBL] [Abstract] [Full Text] [Related]
3. Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
Zhang R; Roque DM; Reader J; Lin J
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35315502
[TBL] [Abstract] [Full Text] [Related]
4. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
5. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance.
Usman RM; Razzaq F; Akbar A; Farooqui AA; Iftikhar A; Latif A; Hassan H; Zhao J; Carew JS; Nawrocki ST; Anwer F
Asia Pac J Clin Oncol; 2021 Jun; 17(3):193-208. PubMed ID: 32970929
[TBL] [Abstract] [Full Text] [Related]
6. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract] [Full Text] [Related]
7. Analyses of merlin/nf2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Shah NR; Tancioni I; Ward KK; Lawson C; Chen XL; Jean C; Sulzmaier FJ; Uryu S; Miller NL; Connolly DC; Schlaepfer DD
Gynecol Oncol; 2014 Jul; 134(1):104-11. PubMed ID: 24786638
[TBL] [Abstract] [Full Text] [Related]
8. A fully human insulin-like growth factor-I receptor antibody sch 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts.
Wang Y; Lipari P; Wang X; Hailey J; Liang L; Ramos R; Liu M; Pachter JA; Bishop WR; Wang Y
Mol Cancer Ther; 2010 Feb; 9(2):410-8. PubMed ID: 20124453
[TBL] [Abstract] [Full Text] [Related]
9. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract] [Full Text] [Related]
10. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study.
Bloss JD; Brady MF; Liao SY; Rocereto T; Partridge EE; Clarke-Pearson DL;
Gynecol Oncol; 2003 Apr; 89(1):148-54. PubMed ID: 12694669
[TBL] [Abstract] [Full Text] [Related]
11. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with sch 58500.
Buller RE; Shahin MS; Horowitz JA; Runnebaum IB; Mahavni V; Petrauskas S; Kreienberg R; Karlan B; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):567-72. PubMed ID: 12082456
[TBL] [Abstract] [Full Text] [Related]
12. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
Labrie F; Luu-The V; Labrie C; Simard J
Front Neuroendocrinol; 2001 Jul; 22(3):185-212. PubMed ID: 11456468
[TBL] [Abstract] [Full Text] [Related]
13. Technology evaluation: sch-58500, Canji.
Barnard DL
Curr Opin Mol Ther; 2000 Oct; 2(5):586-92. PubMed ID: 11249761
[TBL] [Abstract] [Full Text] [Related]
14. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract] [Full Text] [Related]
